Key Highlights

  • Jaguar Health shares closed down 14% at $0.60.
  • The company broadened compassionate-use availability of oral crofelemer to treat an infant with congenital sodium diarrhea-linked intestinal failure.
  • Pediatric data showed decreased parenteral-support dependency and consistent safety.
  • Pivotal microvillus inclusion disease results are anticipated to drive regulatory talks and a 2027 NDA submission.

Jaguar Health, Inc. (NASDAQ: JAGX) shares closed down 14% at $0.60 after the company broadened compassionate-use availability for oral crofelemer to treat an infant with congenital sodium diarrhea-linked intestinal failure.

What Happened

The expansion builds on pediatric data showing decreased parenteral-support dependency and consistent safety. While pivotal microvillus inclusion disease results are anticipated to drive regulatory talks and a 2027 NDA submission, the current update remains focused on clinical access expansion rather than near-term commercial milestones or Capital updates.

Market Reaction

Shares fell despite the compassionate-use expansion, a decline that may reflect investor focus on the absence of near-term commercial or regulatory catalysts accompanying the update.

Outlook

Pivotal microvillus inclusion disease results, expected to support regulatory discussions and a planned 2027 NDA submission, represent the next major disclosed milestone for crofelemer.